TRIALS on going
To date, there are no results from large, well-designed multicentre clinical trials establishing the efficacy of PT in patients with COVID-19.During this period numerous ttrials worldwide are being conducted to assess the efficacy and safety of PT in COVID-19 patients. Six clinical trials are underway in Italy.the first. Table 1 shows the studies in progress in Italy. In most of these studies it will use the dose based on experience published in the literature, 250-300 mL of convalescent plasma will be used to treat each of the patients recruited a maximum of 3 times in 5 days. The main outcomes that will be evaluated are the trend in the concentration of inflammatory markers, the viral load, the remission of clinical symptoms, the number of healings. The various trials conducted in Italy and around the world will provide important EBM that will provide valuable information on the real effectiveness of PT in COVID-19 patients, the right dose to use, the time to take plasma from cured patients, the safety of therapy. (tab.1 )